Who are Emend® (Aprepitant)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fosnetupitant/ palonosetron, Aprepitant plus Ondansetron, Akynzeo solution, Fosaprepitant for Injection, Standard: Aprepitant, Placebo to MK-0954A.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/emend-aprepitant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Emend® (Aprepitant) — Competitive Intelligence Brief

Emend® (Aprepitant) (Emend® (Aprepitant)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NK1 receptor antagonist. Area: Oncology.

phase 3 NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Emend® (Aprepitant) (Emend® (Aprepitant)) — CR-CSSS Champlain-Charles-Le Moyne. Aprepitant blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Emend® (Aprepitant) TARGET	Emend® (Aprepitant)	CR-CSSS Champlain-Charles-Le Moyne	phase 3	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)
fosnetupitant/ palonosetron	fosnetupitant/ palonosetron	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (substance P receptor) / 5-HT3 receptor
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
Akynzeo solution	Akynzeo solution	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
Fosaprepitant for Injection	Fosaprepitant for Injection	Montefiore Medical Center	marketed	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)
Standard: Aprepitant	Standard: Aprepitant	CCTU	phase 3	NK1 receptor antagonist	NK1 receptor
Placebo to MK-0954A	Placebo to MK-0954A	Organon and Co	phase 3	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NK1 receptor antagonist class)

Merck Sharp & Dohme LLC · 4 drugs in this class
GlaxoSmithKline · 3 drugs in this class
Organon and Co · 3 drugs in this class
CCTU · 2 drugs in this class
Acacia Pharma Ltd · 2 drugs in this class
Sanofi · 1 drug in this class
Santen SAS · 1 drug in this class
CR-CSSS Champlain-Charles-Le Moyne · 1 drug in this class
Montefiore Medical Center · 1 drug in this class
New Mexico Cancer Research Alliance · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Emend® (Aprepitant) — Competitive Intelligence Brief. https://druglandscape.com/ci/emend-aprepitant. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab